There’s good news for the estimated 35 percent of the total breast cancer population who  are triple negative and/or have a  high expression of GPNMB.

According to a report in Reuters,  interim results from a mid-stage trial of Celldex Therapeutics Inc’s experimental drug (known as CDX-011) has shown promise for shrinking tumors in patients with advanced breast cancer, working especially well for those with a high level of the protein GPNMB.

GPNMB helps tumor cells “move around”. The thought is that CDX-011 puts the brakes on this movement. In trial patients with GPNMB protein tumor cells, 32 percent responded to the drug, compared with only 13 percent of chemotherapy patients.

For more information visit,

Also, remember to continue to help fund important breast research by donating to breast cancer advocacy organizations such as the Florida Breast Cancer Foundation. You can also contribute by donating household goods and clothing.